A nanocomposite of (NH₂)-MIL-125(Ti)/poly(aniline-co-para-phenylenediamine)/MnFe₂O₄ was developed for synergistic cancer cell eradication via DOX/pCRISPR delivery. The composite consists of amine-functionalized metal-organic frameworks (MIL-125(Ti)) conjugated with a copolymer and coated with manganese ferrite nanoparticles. The study aimed to enhance gene and drug delivery for cancer treatment by improving cellular uptake and transfection efficiency through surface modification with amine groups. An engineered cell-imprinted substrate was used to mimic the cellular environment, enhancing gene delivery and expression in a physiologically relevant microenvironment. The results showed that the nanocomposite successfully co-delivered DOX and pCRISPR, indicating its potential for combination cancer therapy. Key findings include a reliable platform for multi-drug delivery, hemocompatibility with less than 1% hemolysis, enhanced cellular uptake up to 38.3% in A549 cells, and improved therapeutic efficacy through the cell-imprinted substrate. The study highlights the use of innovative strategies to enhance the efficacy of gene and drug therapy against cancer. The nanocomposite, amine surface modification, and cell-mimetic substrate contribute to the development of effective cancer treatments. The study also discusses the importance of surface decoration with polymers to improve the properties of inorganic nanomaterials, the use of MOFs and magnetic nanoparticles for targeted delivery, and the potential of co-delivery systems for enhancing therapeutic efficacy and reducing toxicity. The results demonstrate the effectiveness of the nanocomposite in gene delivery and expression, with high transfection efficiency in A549 cells. The study concludes that the developed nanocomposite has significant implications for cancer treatment, including reduced toxicity, increased specificity, reduced environmental impact, and the potential for personalized medicine. The findings suggest that further research is needed to optimize the nanocomposite for gene delivery and expression, and to explore the use of advanced imaging and sensing techniques for better understanding of nanostructure-cell interactions. The study also emphasizes the importance of ethical and social considerations in the development and application of CRISPR gene editing technology.A nanocomposite of (NH₂)-MIL-125(Ti)/poly(aniline-co-para-phenylenediamine)/MnFe₂O₄ was developed for synergistic cancer cell eradication via DOX/pCRISPR delivery. The composite consists of amine-functionalized metal-organic frameworks (MIL-125(Ti)) conjugated with a copolymer and coated with manganese ferrite nanoparticles. The study aimed to enhance gene and drug delivery for cancer treatment by improving cellular uptake and transfection efficiency through surface modification with amine groups. An engineered cell-imprinted substrate was used to mimic the cellular environment, enhancing gene delivery and expression in a physiologically relevant microenvironment. The results showed that the nanocomposite successfully co-delivered DOX and pCRISPR, indicating its potential for combination cancer therapy. Key findings include a reliable platform for multi-drug delivery, hemocompatibility with less than 1% hemolysis, enhanced cellular uptake up to 38.3% in A549 cells, and improved therapeutic efficacy through the cell-imprinted substrate. The study highlights the use of innovative strategies to enhance the efficacy of gene and drug therapy against cancer. The nanocomposite, amine surface modification, and cell-mimetic substrate contribute to the development of effective cancer treatments. The study also discusses the importance of surface decoration with polymers to improve the properties of inorganic nanomaterials, the use of MOFs and magnetic nanoparticles for targeted delivery, and the potential of co-delivery systems for enhancing therapeutic efficacy and reducing toxicity. The results demonstrate the effectiveness of the nanocomposite in gene delivery and expression, with high transfection efficiency in A549 cells. The study concludes that the developed nanocomposite has significant implications for cancer treatment, including reduced toxicity, increased specificity, reduced environmental impact, and the potential for personalized medicine. The findings suggest that further research is needed to optimize the nanocomposite for gene delivery and expression, and to explore the use of advanced imaging and sensing techniques for better understanding of nanostructure-cell interactions. The study also emphasizes the importance of ethical and social considerations in the development and application of CRISPR gene editing technology.